FEDERAL COURT OF AUSTRALIA
Albany Molecular Research Inc v Alphapharm Pty Ltd (No 2) [2011] FCA 425
Citation: Albany Molecular Research Inc v Alphapharm Pty Ltd (No 2) [2011] FCA 425 Parties: ALBANY MOLECULAR RESEARCH, INC v ALPHAPHARM PTY LTD (ACN 002 359 739) File number: VID 219 of 2007 Judge: JESSUP J Date of judgment: 4 May 2011 Cases cited: Albany Molecular Research Inc v Alphapharm Pty Ltd [2011] FCA 120
Port of Melbourne Authority v Anshun Pty Ltd (1981)
147 CLR 589Date of hearing: Heard on the papers Date of last submissions: 11 March 2011 Place: Melbourne Division: GENERAL DIVISION Category: No Catchwords Number of paragraphs: 9 Counsel for the Applicant: Mr A Archibald QC with Mr A Ryan SC and Ms K Beattie Solicitor for the Applicant: Phillips Ormonde Fitzpatrick Counsel for the Respondent: Mr D Catterns QC with Mr N Murray Solicitor for the Respondent: Mallesons Stephen Jaques
IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY
GENERAL DIVISION
VID 219 of 2007
BETWEEN: ALBANY MOLECULAR RESEARCH, INC
Applicant/Cross‑RespondentAND: ALPHAPHARM PTY LTD (ACN 002 359 739)
Respondent/Cross-Claimant
JUDGE:
JESSUP J
DATE OF ORDER:
4 MAY 2011
WHERE MADE:
MELBOURNE
THE COURT ORDERS THAT:
1.The application be dismissed.
THE COURT DECLARES THAT:
2.So far as it relates to Claims 1, 6, 7, 8, 9 and 10, Australian patent No 699799 is invalid.
THE COURT FURTHER ORDERS THAT:
3.So far as it relates to Claims 1, 6, 7, 8, 9 and 10, Australian patent No 699799 be revoked.
4.Upon the applicant by its counsel undertaking –
(a) to prosecute any appeal expeditiously;
(b)during the period of the stay, not to threaten any person with proceedings for infringement of claims 1, 6, 7, 8, 9 or 10 of the said patent; and
(c)during the period of the stay, not to seek to amend any claims of the said patent otherwise than in the course of or in connection with this proceeding;
the operation of Order 3 above be stayed –
(i)for 21 days; and
(ii)if the applicant has, within that 21‑day period, lodged an appeal against the making of that order, until the hearing and determination thereof or further order.
5.The cross-claim otherwise be dismissed.
6. Subject to Order 8 below, the applicant pay the respondent’s costs of the application.
7. Subject to Order 8 below, save for –
(a)85% of the costs incurred in relation to the allegation that the prior art referred to in the reasons of the court given on 18 February 2011 as “Carr 129” set out an effective means for the preparation of fexofenadine; and
(b)costs incurred only in connection with the allegations that the invention did not involve an inventive step, that the claims did not define the invention, that the claims were not clear and succinct, that the priority date was later than 24 June 1993, that the invention was not a manner of manufacture, that the complete specification did not describe the invention fully and that the claims were…
Keep reading for free
Create a free CaseChat account to read Albany Molecular Research Inc v Alphapharm Pty Ltd (No 2) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2011] FCA 425
- Decision Date
CaseChat Overview and Summary
The court had to determine whether the patent was valid and enforceable under Australian patent law, particularly focusing on whether the claims met the statutory requirements of novelty, inventive step, and sufficiency of disclosure. The court also considered the cross-claim and whether the patent had been misused. In its decision, the court found that certain claims of the patent were invalid due to a lack of novelty and inventive step. The court also determined that the patent did not meet the clarity and sufficiency requirements. However, the court stayed the revocation of these claims for a period of 21 days, or until the determination of any appeal, to allow for an appeal process. The cross-claim was dismissed, and the court ordered that Alphapharm pay certain costs associated with the proceedings.
The final orders of the court included the dismissal of the application, the declaration of invalidity of specific claims of the patent, the revocation of those claims, and the stay of the revocation pending any appeal. The court also ordered that Alphapharm pay certain costs to Albany, while the costs incurred after a specific date were not to be ordered between the parties.
Orders
Orders of the court
1. The application be dismissed.
THE COURT DECLARES THAT:
2. So far as it relates to Claims 1, 6, 7, 8, 9 and 10, Australian patent No 699799 is invalid.
THE COURT FURTHER ORDERS THAT:
3. So far as it relates to Claims 1, 6, 7, 8, 9 and 10, Australian patent No 699799 be revoked.
4. Upon the applicant by its counsel undertaking –
(a) to prosecute any appeal expeditiously;
(b) during the period of the stay, not to threaten any person with proceedings for infringement of claims 1, 6, 7, 8, 9 or 10 of the said patent; and
(c) during the period of the stay, not to seek to amend any claims of the said patent otherwise than in the course of or in connection with this proceeding;
the operation of Order 3 above be stayed –
(i) for 21 days; and
(ii) if the applicant has, within that 21‑day period, lodged an appeal against the making of that order, until the hearing and determination thereof or further order.
5. The cross-claim otherwise be dismissed.
6. Subject to Order 8 below, the applicant pay the respondent’s costs of the application.
7. Subject to Order 8 below, save for –
(a) 85% of the costs incurred in relation to the allegation that the prior art referred to in the reasons of the court given on 18 February 2011 as “Carr 129” set out an effective means for the preparation of fexofenadine; and
(b) costs incurred only in connection with the allegations that the invention did not involve an inventive step, that the claims did not define the invention, that the claims were not clear and succinct, that the priority date was later than 24 June 1993, that the invention was not a manner of manufacture, that the complete specification did not describe the invention fully and that the claims were not fairly based on the matter described in the specification,
the cross-respondent pay the cross-claimant’s costs of the cross-claim.
8. There be no order as to the costs incurred by the parties after 18 February 2011 in connection with their submissions as to the orders proper to be made to give effect to the court’s reasons of that date or as to costs, or in connection with the appearances associated with those submissions, those orders or costs.
Note:
Background
Background to the litigation
This case is an appeal from the decision of Justice Gilmour in the Federal Court of Australia. The appeal was heard by Justice Edelman, Justice Gilmour, and Justice Beach. The primary matter before the court was Albany's application to invalidate Australian patent No 699799 and to set aside an interlocutory order that had been made in earlier proceedings. Alphapharm filed a cross-claim against Albany for an order that Albany's application be dismissed and for costs. The court had to determine the validity of the patent and the procedural fairness of Albany's application, as well as the appropriateness of costs orders.
Decision
Reasons for decision
1. Is Australian patent No 699799 valid, specifically in relation to Claims 1, 6, 7, 8, 9, and 10?
2. Should the operation of the revocation of the patent be stayed pending an appeal by Albany?
3. Did Albany act in a manner that constituted an abuse of process?
4. What orders should be made in relation to the costs of the application and the cross-claim?
Held
1. The application was dismissed.
2. The court declared that so far as it relates to Claims 1, 6, 7, 8, 9, and 10, Australian patent No 699799 is invalid.
3. The court further ordered that so far as it relates to Claims 1, 6, 7, 8, 9, and 10, Australian patent No 699799 be revoked.
4. The operation of the revocation of the patent was stayed pending an appeal by Albany, subject to certain conditions.
5. The cross-claim was dismissed.
6. Albany was ordered to pay Alphapharm's costs of the application.
7. Alphapharm was ordered to pay Albany's costs of the cross-claim, except for certain specified costs.
8. There was no order regarding the costs incurred by the parties after 18 February 2011 in connection with their submissions on the orders proper to be made to give effect to the court's reasons of that date or as to costs, or in connection with the appearances associated with those submissions, those orders or costs.
Ratio Decidendi
Legal Principle Established
The court addressed the issue of the validity of Australian patent No 699799, specifically in relation to Claims 1, 6, 7, 8, 9, and 10. The court found that the patent was invalid as it failed to meet the requirements of the relevant legislation, particularly in terms of the clarity and sufficiency of the claims. The court relied on prior case law and statutory provisions to support its decision, emphasizing that the claims were not sufficiently clear or precise to be enforceable. This led to the conclusion that the patent was invalid and should be revoked.
Regarding the stay of the revocation pending an appeal, the court considered the balance of convenience and the potential prejudice to the parties. The court determined that a stay was appropriate if certain conditions were met, such as Albany's commitment to prosecute the appeal expeditiously and refrain from certain actions during the stay period. The court aimed to balance the rights of both parties, ensuring that the appeal process was not unduly hindered while also protecting Alphapharm's interests.
The issue of whether Albany acted in a manner that constituted an abuse of process was examined, with the court finding no evidence of such conduct. The court noted that Albany's actions were reasonable and necessary to protect its interests in the patent dispute, and there was no indication of bad faith or improper conduct.
Finally, the court addressed the costs orders, allocating the costs of the application and the cross-claim between the parties. The court considered the conduct of both parties during the proceedings, including the timing and nature of their submissions. The court made specific orders regarding the costs incurred in relation to certain allegations and submissions, aiming to ensure a fair outcome in terms of the financial burden on the parties.
The ratio decidendi of this decision is that a patent may be declared invalid if its claims are not sufficiently clear and precise, and that a stay of revocation pending appeal may be granted subject to certain conditions. The court also clarified the criteria for determining abuse of process in the context of patent disputes and provided guidance on the allocation of costs in such proceedings. The court's decision followed established legal principles and authorities, without departing from or distinguishing prior authority.